N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide
• 化学式: C₁₇H₁₆N₄O₃S₂
• 分子量: 388.5
• InChiKey: AEMFAJZFNUUFAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  152
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] HELICASE-PRIMASE INHIBITORS FOR USE IN A METHOD OF TREATING ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE L'HÉLICASE-PRIMASE DESTINÉS À ÊTRE UTILISÉS DANS UNE MÉTHODE DE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：AICURIS GMBH & CO KG

  公开号：WO2014124978A2

  公开（公告）日：2014-08-21

  The present invention relates to the use of helicase-primase inhibitors in a method of treating Alzheimer's Disease (AD). Particularly, the present invention relates to the use of helicase-primase inhibitors in a method of treating AD in a subject that is having HSV-1 infection and is having AD or is having HSV-1 infection and is suspected of having AD. The provided antiviral helicase-primase inhibitors affect the accumulation of the key AD proteins amyloid beta and abnormally phosphorylated tau that occur during HSV-1 infection.